Results 201 to 210 of about 55,599 (265)

International patented medicine prices: how does Canada compare to the OECD? A descriptive analysis of list prices. [PDF]

J Pharm Policy Pract
Dyrkton N, Tam ACT, Guh DP, Anis AH, Zhang W.   +4 more
europepmc   +1 more source

Research Needs in Philippine Pharmaceutical Sciences: A Qualitative Perspective from Regulatory and Clinical Research Sectors of the Pharmaceutical Industry. [PDF]

Acta Med Philipp
Peña IG, Alos HC, Calara NKR, Pavia HGC, Bulatao BPI.   +4 more
europepmc   +1 more source

Access to Essential Medicines in Low- and Middle-Income Countries: A Systematic Review of Barriers and Facilitators. [PDF]

Int J Public Health
Herrera-Ramirez I, Orozco-Nuñez E, Guerra G, Dreser-Mansilla A, Molina-Salazar RE.   +4 more
europepmc   +1 more source

Hospital CBRN preparedness in Lebanon: a modified Delphi-based assessment tool. [PDF]

Emerg Med J
Hitti E, El Zahran T, Chamandi G, Kazzi A, Jabbour R, Bazarbachi N, Azar E, Kazzi Z.   +7 more
europepmc   +1 more source

A Survey on the Implementation of Analytical Quality by Design in Method Development in the Pharmaceutical Industries of Southeast Brazil: Challenges and Opportunities. [PDF]

Ther Innov Regul Sci
Claro BC, Condado EF, Prado LD.
europepmc   +1 more source

Commercial Determinants of Health: Economic and Health Interests Can Be Aligned. [PDF]

Port J Public Health
Perelman J.
europepmc   +1 more source

Antibiotic Use Across One Health Sectors in Uganda: Temporal Alignment Between Antibiotic Introduction and Policy Guidance: A Scoping Review and Meta-Analysis

Nabisubi P, Agasi H, Namutebi S, Nabukeera KC, Akurut E, Ezinga R, Kebirungi G, Kiyaga S, Olum W, Nakanjako D, Kateete DP, Mboowa G, Jjingo D, Muwonge A, Galiwango R.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Pharmaceutical Sector

2020
This chapter presents an overview of the factors involved in valuations of the pharmaceutical industry, most prominently, the FDA requirements that effectively shaped the nature and activities of these firms. The complicated regulatory drug development process, with its several tracks, increases RD both often have inflated IPOs, and both face strict ...
Richard T. Evans, Scott Hinds
openaire   +2 more sources